Methods A retrospective cohort study was undertaken, covering the period from 1997 to 2004, of a 1 000 000-person random sample obtained from Taiwan's National Health Insurance reimbursement database. Between January 1999 and December 2004, 29 759 patients aged 30 years or older were identified as newly diagnosed uncomplicated hypertensive cases. They were followed up until the end of 2004. A time-dependent Cox's proportional hazards model was specified to analyze the risk of stroke development.
Results From the 29 759 uncomplicated hypertensive patients, 1078 new cases of stroke were identified and followed up for at least 1 month during the study period, including 654 ischemic stroke cases. After adjustment for various risk factors, the hazard ratio of developing stroke was significantly higher for poor medication compliance (hazard ratio 1.5-1.9), old age, male sex, and comorbid diabetes mellitus and/or other heart diseases. Different categories of antihypertensive medications were not associated with differential effects on stroke development. In the subsequent analysis, we found that patients receiving pharmacotherapy with beta-blockers were 1.3 (95% confidence interval 1.0-1.6) times more likely to develop ischemic stroke than those who had been treated with other types of antihypertensive medication.
Conclusion Poor medication compliance is a key determinant of developing stroke among hypertensive patients. This study suggests that there has been no differential effect of antihypertensive medication on overall risk of stroke, whereas beta-blockers might be associated with more ischemic stroke. Further studies are needed to corroborate this hypothesis. J Hypertens 27:174-180
Introduction
Hypertension is a highly prevalent health concern on a global scale, for which poor control often leads to the development of ischemic heart disease, stroke, heart failure or renal failure [1] [2] [3] [4] [5] [6] . Numerous studies have shown that antihypertensive pharmacotherapy can effectively reduce the number of premature mortalities and comorbidities associated with hypertension and that good adherence to treatment promotes the effective prevention of various cardiovascular risks including stroke development [7] [8] [9] [10] .
The incidence rate of stroke in Taiwan is higher than those reported in many western countries [11] . Cerebrovascular disease represents the second highest cause of death in Taiwan; at a mortality rate of 57.8 per 100 000 persons per year, this is even higher than the death rate for heart disease. Hypertension has been found to be the main modifiable risk factor for stroke [7, 12] , and although there have been studies examining the incidence of stroke in Taiwan, the current data on risk assessment of stroke in hypertensive patients appear to be inadequate. More importantly, several earlier studies have indicated higher incidences of stroke in hypertensive patients treated with beta-blockers than those treated with alternative drugs [13] [14] [15] [16] [17] [18] .
Consequently, it would seem important to assess whether such an association exists in regular daily practice, because the decisions for treatment in the real world are very complex. The computerized reimbursement data from the National Health Insurance (NHI) Research Database provided us with a good opportunity to undertake such a study. Given that, during the period under examination in this study, the NHI coverage rate was in excess of 96% and the total amount of out-of-pocket payments was very low, our study cohort, based on a nationwide representative random sample, should be suitable for evaluating the relative safety of antihypertensive pharmaceutical therapies in the real world.
The objective of this study was to assess the risk of stroke development among the newly diagnosed uncomplicated hypertensive patients treated with different antihypertensive drugs in Taiwan.
Methods

Study population
We carried out a retrospective cohort study of a 1 000 000-person representative sample obtained from the NHI Research Database, covering the period from January 1997 to December 2004. The computerized reimbursement data file on the 21.4 million persons currently covered by the NHI includes three major elements, inpatient claims, ambulatory care claims and prescriptions dispensed at contracted pharmacies. These provide details of the patients' sex and date of birth, prescription date, drug dosage/duration, commercial names of drugs, and the cost for each prescription.
Patients were identified as hypertensive patients if they had diagnoses of hypertension on at least three occasions using the International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) coding system, and if they had received their initial antihypertensive medication between 1 January 1999 and 31 December 2004. In order to enroll only new patients, we stipulated that there must be a period of at least 2 years (January 1997 to December 1998) during which no antihypertensive treatment and/or diagnoses relating to hypertension were recorded. Most physicians in Taiwan generally manage hypertensive patients in accordance with the Stroke in uncomplicated hypertension Liu et al. 175 recommendations of the US Joint National Committee [10, 19] or the World Health Organization-International Society of Hypertension guideline [20] , and the diagnoses as well as prescriptions reported by physicians in Taiwan are regularly audited by clinical experts in the Bureau of National Health Insurance to ensure that the claims adhere to current guidelines. Thus, the diagnosis of hypertension in the NHI reimbursement database is reliable.
In order to avoid the potential confounding, by comorbidity, of the choice of antihypertensive agents, we excluded all patients with suspected preexisting diagnosis of diabetes mellitus, ischemic heart disease, diseases of pulmonary circulation, stroke, renal disease or other forms of heart disease (including dysrhythmia and heart failure). To ensure the correct application of these exclusion criteria, none of the above should have appeared in any hospitalization diagnoses prior to the patient being diagnosed as hypertensive and should not have appeared more than three times in the ambulatory outpatient files. The process of establishing the target population is summarized in Fig. 1 .
New cases of stroke
Follow-up of this study cohort was subsequently undertaken until the end of 2004 to determine whether any of the sampled patients had developed a new stroke. Stroke was defined as a sudden neurological deficit of presumed vascular origin that lasted longer than 24 h or leading to death [21] . Transient ischemic attacks were not included in this study. Diagnoses of stoke were categorized as subarachnoid hemorrhage, intracerebral hemorrhage, cerebral infarction and acute but ill-defined cerebrovascular disease by ICD-9-CM codes. Clinical diagnoses of stroke have been shown to be reliable [22] . Nevertheless, to further secure the validity of diagnosis, only those patients with no previous history of stroke and diagnosed with stroke after imaging examination by computerized tomography (CT) or MRI in one of the following conditions were considered to be new cases of stroke: diagnosed during the period of hospitalization, diagnosed at an emergency room or diagnosed as stroke at least three times at outpatient clinics.
Available variables
Because all prescriptions for antihypertensive drugs are regularly reimbursed by the NHI in Taiwan, such records relating to all newly treated hypertensive patients aged at least 30 years were retrieved from the reimbursement files on ambulatory care claims and prescriptions dispensed at contracted pharmacies. The different types of antihypertensive medication were categorized according to the major drug classes of angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers, beta-blockers, calcium channel blockers, diuretics and 'others' (all other classes of antihypertensive drugs including alpha-blockers).
On the basis of the sex and age (at the time of the initial treatment for hypertension), patients were divided into four age groups of 30-44, 45-54, 55-64 and 65 or older.
Those patients who developed comorbidity after their initial antihypertensive treatment were classified into the following categories: diabetes mellitus, coronary artery disease, renal disease, hyperlipidemia and 'other' heart diseases.
Because each prescription for a chronic disease, such as hypertension, most frequently involved the prescribing of drugs for 28-day or 30-day periods, we analyzed the time-dependent variables on a month-by-month basis, that is, periods covering 30 days. If patients had received a certain drug for more than 7 days, they would be regarded as having used that drug during that particular month; but if they had received the drug for less than 7 days during a month, then they were regarded as not having used the drug during that particular month.
The patient's compliance rate at time t was calculated as the cumulative number of months with prescribed antihypertensive drugs up to time t divided by the total number of months since the initial antihypertensive prescription up to time t.
Statistical analysis
The SAS statistical software (version 9.1; SAS Institute, Cary, North Carolina, USA) was used in the data analysis. Many variables were assessed on a monthly basis, that is, the state of every time-dependent variable was determined as the state of the patient at the beginning of each period, which lasted for 30 days.
The evaluation of the effects of the various factors on stroke development among our cohort of uncomplicated hypertensive patients was undertaken using a timedependent Cox's proportional hazards model with all the available variables from the reimbursement database, including sex, age, the specific class of antihypertensive medications prescribed, the drug compliance rate, the number of initial antihypertensive drug(s), the mean number of antihypertensive drug(s), comorbidities and so on. The final regression model was obtained using the stepwise variable selection method with both the inclusion and exclusion P value criteria set at 0.15.
After the initial assessment for all types of stroke, we further performed subgroup analyses focusing on ischemic stroke and hemorrhagic stroke, including intracerebral hemorrhage and subarachnoid hemorrhage, separately.
Results
During The results of the multivariate analysis of the effects of various factors associated with stroke development are summarized in Table 1 . The stepwise method revealed that six variables remained in the fitted model. After adjustment for the effects of the relevant time-dependent and time-independent covariates, the hazard ratio was significantly higher for older patients, for male patients and those with a higher average number of drugs.
Patients with a poor compliance were 1.5-1.9 times more likely to develop stroke than those with good adherence to antihypertensive pharmacotherapy. Other significant risk factors for occurrence of stroke were comorbidities of diabetes mellitus and other heart diseases after initiating antihypertensive pharmacotherapy, with estimated hazard ratios of 1.6 and 1.5, respectively. No definite category of antihypertensive drugs was associated with a statistically significant hazard ratio. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DM, diabetes mellitus; HR, hazard ratio. a The hazard ratio for each variable was controlled for age, sex, mean number of antihypertensive drugs, medical compliance, and comorbid diabetes mellitus and/or other heart diseases after antihypertensive treatment.
b The hazard ratio for each variable was controlled for age, sex, medical compliance, and comorbidities after antihypertensive treatment including diabetes mellitus, other heart diseases and renal diseases. patients receiving beta-blockers as compared with those without prescriptions of beta-blockers in the previous month. The results for other covariates were similar to those in the analysis of overall stroke (Table 1) .
Regarding the analysis for hemorrhagic stroke, old age (65 years), male sex, higher mean number of antihypertensive drugs (hazard ratio 1.7, 95% CI 1.3-2.2) and poor drug compliance (hazard ratios 1.7-3.1) were statistically significant covariates that stayed in the fitted model.
The crude incidence rates of ischemic stroke among patients receiving various categories of antihypertensive medication are shown in Table 2 . After controlling for the effect of potential confounders using the time-dependent Cox's proportional hazards model, only the hazard ratio for beta-blockers was significantly greater than 1. Among the 98 ischemic stroke cases with antihypertensive pharmacotherapy containing a beta-blocker, 40 patients (40.8%) were receiving monotherapy, whereas the others were using combination therapy with other antihypertensive drugs. Such a proportion seemed similar to that of all patients receiving beta-blockers, or 35.4%.
The frequency distribution of acute ischemic stroke cases for various agents of beta-blockers is provided in Table 3 . The hazard ratio of ischemic stroke was significantly greater for atenolol (1.4; 95% CI 1.1-1.9) according to the fitted time-dependent Cox's proportional hazards model.
Discussion
We conducted a retrospective cohort study using the computerized reimbursement database to assess the risk of stroke in uncomplicated hypertensive patients treated with various antihypertensive medications. According to the fitted time-dependent Cox's proportional hazards model, the hazard ratios of developing stroke were significantly higher for older and male hypertensive patients and among those with comorbidities of diabetes and heart disease, which were compatible with many of the previous studies [11, 23, 24] . We also found that poor compliance with antihypertensive pharmacotherapy was an important risk factor in stroke development, for both ischemic and hemorrhagic types.
Although a higher risk of stroke for patients treated with beta-blockers has been documented in prior randomized controlled trials and meta-analyses of such studies [13] [14] [15] [16] [17] [18] , we found no evidence of a differential effect of antihypertensive pharmacotherapy on stroke risk when all stroke subtypes were included in the multivariate analysis. Our findings indicated that outcome research might provide additional evidence for improving clinical guidelines, as the processes in randomized clinical trials might not be able to take care of all conditions in the daily practices of clinicians. For all types of stroke among these low-risk, uncomplicated hypertensive patients in our study, the control of their hypertension seemed to be a more important factor than the choice of antihypertensive agent, because those patients who needed more combinations of antihypertensive drugs might have a higher ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; HR, hazard ratio. a The adjusted hazard ratio for each category of antihypertensive drug has been controlled for age, sex, medical compliance, and comorbidities after antihypertensive treatment including diabetes mellitus, other heart diseases and renal diseases.
b P < 0.05. risk of overall stroke. Such kind of trend was even more apparent for hemorrhagic stroke in the subgroup analysis, despite the small number of cases.
The prior studies in this area have documented an association between poor medication compliance and the failure to control hypertension [10, 25] , and indeed, we did find that hypertensive patients with poor medication compliance remained at a higher risk of stroke than those with better medication compliance, which probably came as a result of their higher blood pressure (BP) level. This association was consistent for all types of stroke in our analysis. However, our results did not reveal a linear doseresponse relationship, indicating the complexity of the behavior of such patients [26] [27] [28] . Nevertheless, the relatively low compliance rate in these real-life data from Taiwan indicates significant room for improvement in patients' adherence to antihypertensive pharmacotherapy.
In the subsequent analysis restricted to ischemic stroke, we observed an excess risk of ischemic stroke associated with beta-blocker therapy, when compared to treatment with other antihypertensive therapies. The possible mechanisms are not clear yet. Some researchers attributed the modest effect of beta-blockers on stroke prevention to their smaller ambulatory BP reduction, whereas Williams et al. [29] reported that beta-blockers could have inferior cardiovascular outcome that resulted from different effects on central aortic pressures and hemodynamics despite similar effects on brachial BP. We had no BP control data from the NHI reimbursement database. However, because only newly treated uncomplicated hypertensive patients were enrolled for this study, the likelihood of initiating beta-blockers after patients' hypertension became more severe might be low [30] . Moreover, the number of antihypertensive medication, which was taken as a proxy for the severity of hypertension, was not a significant factor for developing ischemic stroke in our analysis. It seemed that the greater risk of ischemic stroke for beta-blockers could not be directly attributed to severe hypertension or higher BP. Thus, we suspected that the progression of atherosclerosis, aggravated by the slowing down of the circulatory system, as a direct result of the use of beta-blockers, might be responsible for the increased risk of ischemic stroke development.
This study has some limitations. First of all, because of protection of privacy, we are not allowed to link the NHI reimbursement database with private medical records to obtain the BP measurements or results of laboratory tests. The BP data are important in predicting the risk of stroke; nonetheless, we have associated the exposure of antihypertensive drugs directly with the clinical outcome rather than the surrogate -BP. Another concern is the potential residual confounding of the differential distributions of higher body mass indices (BMI), serum triglyceride levels, creatinine concentration levels and fasting blood glucose levels in patients treated with different antihypertensive medications [31] , although covariates representing later development of diabetes mellitus, hyperlipidemia and renal disease have been controlled in the regression model. We hoped to consider BMI, as well. However, because the current recommended practice does not differentiate between the prescriptions of antihypertensive medications based on the BMI, we suspected that BMI would not likely confound the effect of antihypertensive drugs upon developing stroke, as was supported by several studies showing that the association between a high BMI and stroke was substantially attenuated after adjustment for hypertension and other major risk factors [32] [33] [34] .
In conclusion, this study highlights that the importance of good compliance with antihypertensive therapy can never be overstated with regard to effective stroke prevention. The control of hypertension played a major role in determining the risk of stroke among the previously uncomplicated hypertensive patients. After controlling other major potential confounding factors, we found no differential risks of stroke related to any type of antihypertensive medication, whereas some unintended association between the pharmacotherapy with betablockers and a higher risk of ischemic stroke was observed in the subgroup analysis. Further studies will be required to gain a better understanding of the underlying pathophysiological mechanisms of preventing stroke among hypertensive patients through different antihypertensive medications.
